<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>CNS</title><link>https://nrouizem.github.io/test/cns_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/cns_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Sun, 16 Mar 2025 01:23:24 +0000</lastBuildDate><item><title>How 3T Biosciences’ platform targets immunologically cold solid tumors</title><link>https://www.drugdiscoverytrends.com/3t-biosciences-targeted-strategy-for-mss-colorectal-cancer/</link><description>3T Biosciences is addressing the challenge of immunotherapy resistance in solid tumors, particularly focusing on microsatellite stable colorectal cancer (MSS CRC), which shows over 90% non-responsiveness to checkpoint inhibitors. Their innovative platform aims to enhance treatment efficacy for these immunologically cold solid tumors, promising a potential breakthrough in oncology.</description><pubDate>Sat, 01 Feb 2025 05:12:51 +0000</pubDate></item><item><title>How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments</title><link>https://www.drugdiscoverytrends.com/how-capsidas-unconventional-funding-strategy-and-capsid-technology-promise-to-reshape-cns-treatments/</link><description>Capsida Biotherapeutics, a gene therapy startup, announced that AbbVie will exercise its option on their first neurodegenerative disease program, resulting in a $40 million license payment. The company has successfully built its funding through partnerships with major pharmaceutical firms, leveraging its innovative capsid technology to advance treatments for CNS disorders.</description><pubDate>Sat, 01 Feb 2025 21:05:12 +0000</pubDate></item><item><title>Landmark Bio’s mission to prevent cell therapy ‘do-overs’</title><link>https://www.drugdiscoverytrends.com/landmark-bios-mission-to-prevent-cell-therapy-do-overs/</link><description>Landmark Bio is focused on helping biotech startups avoid the pitfalls of rushing into first-in-human trials without adequate planning for large-scale manufacturing. The company aims to streamline the development process and prevent costly setbacks in cell therapy production.</description><pubDate>Tue, 04 Feb 2025 15:58:57 +0000</pubDate></item><item><title>The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root</title><link>https://www.drugdiscoverytrends.com/the-fda-fast-tracked-gnsc-001-gene-therapy-targets-osteoarthritis-at-its-root/</link><description>The FDA has fast-tracked GNSC-001, a gene therapy aimed at addressing osteoarthritis at its source, responding to a significant medical need for effective treatments for the over 30 million Americans affected by the disease. With osteoarthritis costing the U.S. healthcare system $459.5 billion annually, this innovative therapy represents a potential breakthrough in managing this degenerative joint condition.</description><pubDate>Tue, 04 Feb 2025 19:16:27 +0000</pubDate></item><item><title>A B-vitamin rescues Parkinson-like damage in flies, pointing to new neuroprotective strategy</title><link>https://www.drugdiscoverytrends.com/a-b-vitamin-rescues-parkinson-like-damage-in-flies-pointing-to-new-neuroprotective-strategy/</link><description>Biotin (vitamin B7) has shown promise as a neuroprotective agent against manganese-induced neurotoxicity related to Parkinson's disease, according to a recent study that utilized fruit fly models and human dopaminergic neurons. The findings suggest that biotin supplementation could reverse neurological damage caused by excessive manganese exposure, offering potential new strategies for neuroprotection.</description><pubDate>Thu, 27 Feb 2025 02:10:50 +0000</pubDate></item><item><title>Q&amp;A: AnaptysBio’s CMO on rosnilimab’s ‘compelling’ phase 2b RA results</title><link>https://www.drugdiscoverytrends.com/qa-anaptysbios-cmo-on-rosnilimabs-compelling-phase-2b-ra-results/</link><description>AnaptysBio has announced promising results from its Phase 2b RENOIR clinical trial for the investigational therapy rosnilimab, with nearly 70% of participants achieving low disease activity by Week 14. The therapy successfully met its primary endpoint by showing statistically significant improvements in DAS28‑CRP scores at Week 12 compared to placebo.</description><pubDate>Fri, 28 Feb 2025 16:41:52 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>Roche launches new Boston center; NIH centralizes peer review</title><link>https://www.biopharmadive.com/news/roche-boston-center-nih-peer-review-pfizer-james-list/741901/</link><description>Swiss pharma giant Novartis announced plans to centralize its cardiometabolic drug research at a new Allston, Massachusetts, hub, signaling a strategic focus on heart and metabolic disease innovation. Meanwhile, AskBio progressed a mid-phase gene therapy trial, and Pfizer tapped a GLP-1 expert, intensifying competition in the weight-loss and diabetes therapeutics race.</description><pubDate>Fri, 07 Mar 2025 16:20:00 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>How bluebird's buyout offer went from $100M upfront to $29M</title><link>https://endpts.com/how-bluebirds-buyout-offer-went-from-100m-upfront-to-29m/</link><description>Bluebird bio, once a gene therapy darling valued at $10 billion in 2018, was sold last month for just $29 million upfront in a fire sale, marking a dramatic fall amid sector struggles. The article hints at further challenges, noting “it almost…” but leaves the story unfinished, suggesting deeper turmoil or near-catastrophe in its trajectory.</description><pubDate>Fri, 07 Mar 2025 18:25:38 +0000</pubDate></item><item><title>FDA approves Neurotech therapy for rare eye disease</title><link>https://endpts.com/fda-approves-neurotech-therapy-for-rare-eye-disease/</link><description>The FDA approved Neurotech Pharmaceuticals’ first-of-its-kind cell therapy for macular telangiectasia type 2, a rare eye disease causing progressive central vision loss, marking a major advancement for patients with no prior treatment options. The therapy, which implants cells to repair retinal damage, could transform care for the condition, though the article does not mention specific business deals or partnerships related to its development.</description><pubDate>Fri, 07 Mar 2025 19:57:13 +0000</pubDate></item><item><title>J&amp;J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu</title><link>https://www.biospace.com/drug-development/j-js-oral-il-23r-blocker-sets-new-standard-in-plaque-psoriasis-beating-bmss-sotyktu</link><description>New late-stage trial data reveals Johnson &amp; Johnson’s psoriasis drug icotrokinra outperformed Bristol Myers Squibb’s Sotyktu in clearing skin and reducing symptom severity for patients with plaque psoriasis. The findings could intensify competition in the dermatology treatment market, positioning J&amp;J’s therapy as a potential challenger in this therapeutic area.</description><pubDate>Mon, 10 Mar 2025 14:03:00 +0000</pubDate></item><item><title>Arrowhead reveals small batch of open-label data for 'non-core' kidney drug</title><link>https://endpts.com/arrowhead-reveals-small-batch-of-open-label-data-for-non-core-kidney-drug/</link><description>Arrowhead Pharmaceuticals unveiled promising new open-label data from its ARO-C3 RNAi therapy program, showing potential to improve kidney disease outcomes by targeting complement pathways in a small study involving about a dozen patients. The early-stage results highlight the therapy's novel approach to addressing kidney disorders, though no partnerships or business deals related to the program were disclosed.</description><pubDate>Mon, 10 Mar 2025 15:07:58 +0000</pubDate></item><item><title>Mineralys shares climb on study data for blood pressure drug</title><link>https://www.biopharmadive.com/news/mineralys-lorundrostat-hypertension-study-results/742000/</link><description>New studies on Mineralys' hypertension treatment have validated the drug as a promising near-commercial product, with analysts hailing it as a "derisked, almost-commercial stage cardiometabolic asset." While no specific deals or partnerships were mentioned, the data bolsters the therapy’s market potential and positions it for future commercial opportunities.</description><pubDate>Mon, 10 Mar 2025 15:30:00 +0000</pubDate></item><item><title>Mineralys’ Hypertension Drug Drops Blood Pressure in Phase II/III, Setting Up Market Clash</title><link>https://www.biospace.com/drug-development/mineralys-hypertension-drug-drops-blood-pressure-in-phase-ii-iii-setting-up-market-clash</link><description>Mineralys Therapeutics saw its stock surge over 50% after announcing successful Phase 2 trial results for its hypertension drug, which significantly reduced blood pressure in patients across two clinical studies. The promising data positions the therapy as a potential leader in the $30 billion hypertension market, heightening investor interest in the company’s future regulatory and commercial plans.</description><pubDate>Mon, 10 Mar 2025 16:11:28 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>Novo’s Wegovy successor disappoints in second large trial</title><link>https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/</link><description>A recent study found that CagriSema, a weight-loss therapy for individuals with obesity and diabetes, demonstrated effectiveness in aiding weight loss but fell short of outperforming Eli Lilly’s rival drug Zepbound. While the results highlight CagriSema’s potential, they solidify Zepbound’s competitive edge in the burgeoning metabolic treatment market.</description><pubDate>Mon, 10 Mar 2025 17:17:00 +0000</pubDate></item><item><title>Beam base editing therapy gets ‘proof of concept’ in rare lung disease</title><link>https://www.biopharmadive.com/news/beam-aatd-base-editing-initial-data-results-302/742015/</link><description>Beam Therapeutics' shares dropped sharply despite promising early study results showing its gene-editing technology could address the genetic cause of alpha-1 antitrypsin deficiency. The stock decline highlights investor concerns even as the company advances its innovative treatment potential.</description><pubDate>Mon, 10 Mar 2025 17:25:00 +0000</pubDate></item><item><title>Virtual physical therapy startup Hinge Health files to go public</title><link>https://endpts.com/virtual-physical-therapy-startup-hinge-health-files-to-go-public/</link><description>Hinge Health, a virtual physical therapy startup focused on treating musculoskeletal issues and chronic pain through remote software, has filed for an IPO, ending a lull in digital health public offerings. The company aims to list on a stock exchange, marking a potential resurgence in investor confidence for the telehealth sector.</description><pubDate>Tue, 11 Mar 2025 04:00:11 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD</title><link>https://www.biospace.com/drug-development/beams-gene-editor-achieves-first-ever-genetic-correction-in-aatd</link><description>William Blair analysts highlighted BEAM-302 as a breakthrough therapy, praising its superior efficacy in its sector in a recent investor note. While the report emphasized the drug's potential to redefine treatment standards, it did not mention any specific business deals, partnerships, or acquisitions related to the product.</description><pubDate>Tue, 11 Mar 2025 13:52:59 +0000</pubDate></item><item><title>2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M</title><link>https://www.biopharmadive.com/news/2seventy-bio-bristol-myers-deal-abecma-bluebird/742142/</link><description>2Seventy Bio's recent acquisition has terminated its brief stint as an independent firm, marking the end of a turbulent period marked by strategic restructuring and asset sales. The company, which shed research segments and saw its market value plummet by nearly 100%, now shifts focus under new ownership amid financial struggles.</description><pubDate>Tue, 11 Mar 2025 16:05:00 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Viking inks CordenPharma deal to boost obesity drug supply</title><link>https://www.biopharmadive.com/news/viking-cordenpharma-obesity-drug-manufacturing-deal/742139/</link><description>A biotech firm is investing $150 million in a strategic alliance to secure expanded production capacity for a high-profile weight-loss therapy, positioning itself to meet soaring demand. The partnership underscores the company’s aggressive push to capitalize on the competitive but rapidly growing market for obesity treatments.</description><pubDate>Tue, 11 Mar 2025 17:25:00 +0000</pubDate></item><item><title>Montara Therapeutics adds $20M to seed fundraise for neurology pipeline</title><link>https://endpts.com/montara-therapeutics-adds-20m-to-seed-fundraise-for-neurology-pipeline/</link><description>Montara Therapeutics has secured $20 million in expanded seed financing to propel its preclinical CNS candidate pipeline, targeting long-standing safety issues in research and development. This funding will support the company's efforts in developing innovative solutions in the central nervous system space.</description><pubDate>Thu, 13 Mar 2025 12:00:29 +0000</pubDate></item><item><title>MeiraGTx partners with cryptic AI startup Hologen to advance Parkinson's gene therapy</title><link>https://endpts.com/meiragtx-partners-with-cryptic-ai-startup-hologen-to-advance-parkinsons-gene-therapy/</link><description>MeiraGTx is spinning out its Parkinson's disease program into a new company in collaboration with a mysterious AI startup co-founded by former Google CEO Eric Schmidt. This strategic partnership aims to enhance the development of innovative gene therapies for the treatment of Parkinson's disease.</description><pubDate>Thu, 13 Mar 2025 15:32:22 +0000</pubDate></item><item><title>Third indication beckons for Amgen's Uplizna</title><link>https://pharmaphorum.com/news/third-indication-beckons-amgens-uplizna</link><description>Amgen is set to submit a third indication for its therapy Uplizna, aimed at treating generalized myasthenia gravis with a dosing schedule of twice a year. This follows promising results from a recent phase 3 trial.</description><pubDate>Fri, 14 Mar 2025 10:13:05 +0000</pubDate></item><item><title>EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia</title><link>https://www.pharmaceutical-technology.com/news/ec-otsuka-lundbeck-rxulti/</link><description>The European Commission has granted approval for Otsuka Pharmaceutical and Lundbeck's atypical oral antipsychotic, Rxulti (brexpiprazole), to be used in the treatment of schizophrenia. This approval marks a significant advancement in the options available for managing this mental health condition.</description><pubDate>Fri, 14 Mar 2025 10:42:42 +0000</pubDate></item><item><title>MeiraGTx and Hologen launch AI-backed gene therapy venture</title><link>https://www.pharmaceutical-technology.com/news/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture/</link><description>MeiraGTx is set to advance its Parkinson's gene therapy into Phase III trials, backed by a substantial funding commitment of up to $430 million from Hologen. This partnership aims to accelerate the development of innovative treatments for Parkinson's disease.</description><pubDate>Fri, 14 Mar 2025 11:27:54 +0000</pubDate></item><item><title>Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’</title><link>https://www.biopharmadive.com/news/makary-help-vote-acelyrin-pliant-poison-pills-sutro-jobs/742531/</link><description>President Trump's nominee to lead the FDA received approval from the Senate HELP Committee. Meanwhile, Sutro Bio cut jobs as a cell and gene therapy pilot program showed promising results.</description><pubDate>Fri, 14 Mar 2025 15:57:00 +0000</pubDate></item></channel></rss>